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Abstract
The study of cancer, a highly heterogeneous disease with different causes and clinical out-
comes, requires a multi-angle approach and the collection of large multi-omics datasets
that, ideally, should be analyzed simultaneously. We present a new pathway relevance
ranking method that is able to prioritize pathways according to the information contained in
any combination of tumor related omics datasets. Key to the method is the conversion of all
available data into a single comprehensive network representation containing not only
genes but also individual patient samples. Additionally, all data are linked through a network
of previously identified molecular interactions. We demonstrate the performance of the new
method by applying it to breast and ovarian cancer datasets from The Cancer Genome
Atlas. By integrating gene expression, copy number, mutation and methylation data, the
method’s potential to identify key pathways involved in breast cancer development shared
by different molecular subtypes is illustrated. Interestingly, certain pathways were ranked
equally important for different subtypes, even when the underlying (epi)-genetic distur-
bances were diverse. Next to prioritizing universally high-scoring pathways, the pathway
ranking method was able to identify subtype-specific pathways. Often the score of a path-
way could not be motivated by a single mutation, copy number or methylation alteration, but
rather by a combination of genetic and epi-genetic disturbances, stressing the need for a
network-based data integration approach. The analysis of ovarian tumors, as a function of
survival-based subtypes, demonstrated the method’s ability to correctly identify key path-
ways, irrespective of tumor subtype. A differential analysis of survival-based subtypes
revealed several pathways with higher importance for the bad-outcome patient group than
for the good-outcome patient group. Many of the pathways exhibiting higher importance for
the bad-outcome patient group could be related to ovarian tumor proliferation and survival.
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Introduction
Uncovering the molecular mechanisms that give tumor cells their growth advantage remains a
fundamental challenge in cancer research. This task is non-trivial because cancer is a complex
disease: a tumor’s growth advantage often is not caused by genetic alterations of a single type
but rather by a combination of defects of different types. Consequently, the study of tumor
development and progression requires the availability of different types of data. Each data type
can capture a different aspect of the tumor’s deviating (epi-) genetic state and metabolism.
Because of the diverse causes of cancer, the success of applying any tumor analysis method is
uncertain if it operates only on part of the available data.
Furthermore, when one is concerned with revealing the mechanism of action underpinning
the tumor’s growth advantage, a network- or pathway-based approach is crucial. Because of
the clonal nature of tumor cells, true oncogenic alterations (contrary to e.g. passenger muta-
tions that don’t contribute to the tumors fitness) are sparse. Patients with the same disease phe-
notype often will not share any somatic mutations occurring in the same pathway [1–5]. This
so-called mutual exclusivity of somatic mutations, a concept that can be extended to other data
types, renders the statistical task of identifying true genomic causes of cancer challenging and
motivates ‘pathway driven’ analysis [1,4,6,7]. Such an analysis is no longer gene-centric, but
exploits the fact that interacting genes constitute pathways, connecting upstream genetic dis-
turbances (causes) with downstream effects. For tumors to exhibit a similar molecular or clini-
cal phenotype, it is not required that they share the same disturbances in the same individual
genes. Instead the same pathways will be impacted by possibly many combinations of (epi-)
genetic alterations. These pathways can be identified by pooling the information present in dif-
ferent independently evolved tumors.
Tackling tumor analysis problems consequently not only requires multi-omics datasets and
large patient cohorts, but also largely depends on the availability of an analysis framework that
can integrate data of different types in a biologically relevant way [1,8–10]. We present a net-
work-based data integration strategy that uses sets of genes (pathways) as the unit of analysis
rather than individual genes. In contrast to existing tumor analysis methods, addressing either
patient subtyping [1,11], driver gene prioritization [2–4,12,13], pathway impact assessment
[6,7,14] or interaction network delineation [1,5,15], our method takes as input any combination
of data (e.g., gene expression, mutation, copy number and methylation data). It allows for the
ranking of pathways according to their relevance for a set of patients. To achieve this, all avail-
able data are cast into a unique network model. The model not only contains genes, but also the
individual patients and prior knowledge in the form of a network of known gene interactions
derived from public databases. Including patient samples as entities in the integrated network
allows for quantifying the relevance of groups of genes for groups of patient samples using an
intuitive measure of connectedness in this network representation. The gene interactions added
as prior knowledge introduce mechanistic relations between individual genes in the network
and will help relating diverse upstream genetic disturbances in the same pathway to the same
molecular (downstream) phenotype, e.g. over– or under-expression of another set of genes.
Our contribution consists of a new method for pathway impact assessment. The method
ranks a set of predetermined pathways according to their relevance for a given set of patient
samples, and allows for the integration of any data type that can be cast into a binary relation
between a gene and a sample or patient. It is an intuitive alternative to other methods incorpo-
rating pathway topology in their analysis like Signaling Impact Analysis [14] operating exclu-
sively on gene expression data, and PARADIGM [6] operating on gene expression and copy
number data. Both methods do not support the inclusion of mutation data. PARADIGM
SHIFT [7], an extension of PARADIGM, does handle mutation data, but it is targeted
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specifically at the prediction of the nature of mutations by analyzing their downstream effects.
We applied our method to two datasets from The Cancer Genome Atlas (TCGA), breast cancer
[9] and ovarian cancer [16]. The method’s ability to rank pathways that are relevant to homo-
geneous groups of patients is demonstrated using the simultaneous analysis of mutation,
mRNA expression, copy number and methylation data sets.
Materials and Methods
Pathway relevance ranking using network-based data integration
We present an unsupervised analysis method that combines different data types with prior
knowledge resulting in a comprehensive network representation (see below). Key to the
method is the representation of all available data in a single network (referred to as the global
network). This network contains all entities under study (patient samples, differentially
expressed genes, genes containing mutations, . . .) and their mutual relations derived from
either the data themselves or from prior knowledge. Using this global network representation,
a similarity measure that expresses the degree to which network entities are related to each
other can be calculated. Those similarities are subsequently used to assess the relevance of dif-
ferent pathways for a set of patient samples. The pathways, or more general, the sets of genes
under study, need to be specified in advance. The proposed method ranks the predefined path-
ways according to their relevance for a set of samples. An overview of the method is given in
Figs 1 and 2. A reference implementation is available for download from http://bioinformatics.
intec.ugent.be/pathwayranking.
Global network construction. The construction of the global network is demonstrated
using gene expression, mutation, methylation, and copy number data. Input datasets are
required to contain data for all samples, but can contain data different genes. Datasets can be
omitted, and any data that can be converted into a binary form can be added. Indeed all contin-
uous data are necessarily made binary (see Data section). A ‘1’ corresponds to either over- or
under-expression (i.e., differential expression), copy number amplification or loss, mutation or
hyper- or hypo-methylation. Conversely, a ‘0’ corresponds to normal expression, normal copy
number, the absence of mutations or a normal methylation pattern. Treating over-expression
of a gene identically to under-expression (and analogously, treating copy number amplification
and loss, and hyper- and hypo-methylation in the same way) may seem as an oversimplifica-
tion. In practice, when studying homogeneous groups of samples (e.g., belonging to an identi-
cal subtype), it is less likely that some samples in this homogeneous group would exhibit over-
expression and others under-expression of the same gene. A ‘1’ in a binary dataset merely
reflects an abnormal state of a gene for a particular sample, and we assume that this state of
abnormality will be similar for samples exhibiting the same disease phenotype. Note that
because expression data of tumor samples are analyzed relative to expression data of normal
samples (see Data section), differential expression in this context does not necessarily corre-
spond to absolute high or absolute low expression.
To construct the global network, first each binary input dataset is represented as an individ-
ual network (Fig 1a). This is achieved by converting each ‘1’ in the binary data to an undirected
link connecting a sample node (labelled S1-3 in Fig 1) with a gene node (labelled a-g). For exam-
ple, if gene a is over-expressed in sample S1, a link between node S1 and node a is created. As a
result, four separate networks (one for each input dataset) are created. Next, the individual net-
works are merged (Fig 1b). In the merging process, sample nodes are joined (e.g., the resulting
global network only contains one sample node S1) but gene nodes are not. Gene nodes repre-
sent an abnormal state for which the interpretation is different for each input dataset. A gene
can be differentially expressed, mutated, etc. and merging genes nodes would discard this
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PLOS ONE | DOI:10.1371/journal.pone.0133503 July 28, 2015 3 / 22
Fig 1. Global network construction. (a)Conversion of binary data to a network representation. All continuous data are mapped to a binary representation
with ‘1’ (colored squares) corresponding to a gene with a value deviating from normal for a particular sample. Each ‘1’ in the binary datasets is converted to
an undirected link (solid line) between a gene node and a sample node. Prior knowledge, derived from public gene interaction repositories, is available in the
form of undirected links (dashed grey line) between genes. Characters a-g correspond to gene IDs, S1-S3 represent sample IDs. (b) Construction of the
global network. The network representations of the binary datasets and the prior knowledge network are merged to constitute a single comprehensive
network representation. Gene nodes originating from the input datasets are connected to the corresponding gene in the prior knowledge interaction network
Pathway Relevance Ranking through Network-Based Data Integration
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information. Consequently, the network will contain multiple gene nodes with the same gene
identifier. For example, in Fig 1b, gene a is present multiple times, once as a differentially
expressed gene, and once as a mutated gene.
Additionally, in order to connect heterogeneous and potentially sparse genetic aberrations
with their downstream effects on gene expression, prior information in the form of known
gene interactions is incorporated. The prior knowledge interaction network will ensure that a
pathway is not treated as an isolated group of genes. Instead, the genes in pathway are analyzed
not only relative to each other, but also relative to other pathways that may or may not overlap
with the pathway under study. New nodes representing genes involved in known gene interac-
tions are created. These ‘interaction nodes’ are connected with undirected links whenever an
interaction between these nodes exists (Fig 1a and 1b). Then, the genes derived from the input
datasets, representing the different abnormal states, are connected to the interaction node with
(dashed yellow lines). (c) The resulting adjacency matrix representation of the undirected global network. For clarity, individual gene and sample identifiers
are omitted. NET (grey) = genes from the prior knowledge interaction network, S (dark blue) = samples, EXP (green) = genes from the gene expression
dataset, CNV (pink) = genes from the copy number dataset, MUT (light blue) = mutated genes, MET (orange) = methylated genes. (d) The similarity matrix
derived from the adjacency matrix, indicating the parts of the similarity matrix that are relevant for the pathway ranking task.
doi:10.1371/journal.pone.0133503.g001
Fig 2. Pathway relevance scoring.Given a subset of the global similarity matrix (Sexp Scnv, Smut, Smet, see Fig 1) and a set of genes (a,b,d) constituting a
pathway P, a score for each input dataset is calculated by first removing genes from Sexp Scnv, Smut, Smet that do not belong to the pathway and then taking
the average of all remaining values in Sexp Scnv, Smut, Smet. This process is repeated for n randomly generated gene sets (with the same number of genes as
the pathway P) yielding n scores for each input dataset. The random pathway scores are used to calculate a p-value for obtaining the pathway scores purely
by chance. The resulting p-values are multiplied, resulting in a single aggregated pathway score.
doi:10.1371/journal.pone.0133503.g002
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the same identifier. For example, the two a nodes in Fig 1b, representing a differentially
expressed and mutated state of gene a, are both connected to a single interaction node a.
Note that the newly constructed global network no longer corresponds to a physical or func-
tional gene interaction network. Instead, the network representation is a convenient means for
integrating different types of data, including prior knowledge. This is possible because all links
in the network can be identically interpreted, i.e. as a qualitative “is relevant to” relation.
Because the network is treated as undirected, the resulting adjacency matrix representation is
symmetric. As illustrated in Fig 1c, several parts of the adjacency matrix remain empty.
Network-based similarity calculation. The adjacency matrix representation of the global
network (Fig 1c) is used to derive the similarity (a quantitative measure of relevance or impor-
tance) between samples and the gene nodes representing the abnormal states of the genes in
the different datasets. The similarities are summarized in the global similarity matrix (Fig 1d).
Similarity measures based on shortest path calculations would be an intuitive choice, but these
measures have been shown to underperform, especially when data are qualitative, incomplete
or of unknown reliability [17,18]. Because of their good performance [18–21], we used kernels
calculated on graph nodes. A great multitude of kernels on graph nodes exist (see [22] for a
comprehensive overview). Preliminary experiments suggested that the Laplacian Exponential
Diffusion (LED) kernel yields stable results. It is calculated on the weighted Laplacian matrix L
as follows [22]:
L ¼ D A
Dði; iÞ ¼
Xn
j¼1
Aði; jÞ
KLED ¼ expðaLÞ
Here n is the number of entities in the global network, D is the diagonal degree matrix and A(i,
j) represents entry j on row i of the global network’s adjacency matrix A. KLED(i,j) contains, at
time t = α, the quantity found in node i when a unit quantity starts diffusing from node j at
t = 0. The exp-operator indicates the matrix exponential. Calculating KLED results in a similar-
ity matrix with the same size as the original global adjacency matrix. Before continuing with
the analysis, additional normalization of the similarity matrix is performed by exploiting the
kernel properties of a kernel matrix K with elements kij:
KNði; jÞ ¼
kijﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
kii  kjj
q
Pathway relevance ranking. When assessing pathway importance, the goal is to identify
which pathways—containing active or inactive genes, mutated genes, genes with altered copy
number or hyper- or hypo-methylated genes—are more relevant for a group of samples than
others. Pathway relevance will typically correspond to abnormal behavior like activation or
silencing and/or to the presence of genomic alterations. The pathways of interest should be
available as sets of genes. Providing topology information for the pathways of interest is unnec-
essary, as the relations between genes are provided by the prior knowledge interaction network.
The pathway ranking problem can be addressed by focusing on the submatrices Sexp, Smut,
Scnv and Smet derived from the global similarity matrix (Figs 1d and 2). These submatrices rep-
resent the similarities between the considered patient samples and genes measured in
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respectively the expression, mutation, copy number and methylation datasets. A high value for
a sample-gene similarity indicates greater importance or relevance of a gene for that sample,
and low values suggest that the gene is not important for the sample. Although each entry in
these submatrices expresses a similarity between a sample and a gene present in one of the
aforementioned datasets, the similarities are calculated using the entire global network. The
similarity metric exploits the fact that the pathways under study are not isolated entities in the
global network (note that the global network is more comprehensive than the prior knowledge
interaction network). If the pathways were isolated entities, the average similarity per pathway
would correspond to the average number of ‘ones’ in the pathway. Instead, pathways are inter-
connected through a number of mechanisms: (1) samples having ‘abnormal’ genes in different
pathways or in different types of data will act as bridges between pathways and datasets, (2)
pathways will typically intersect or overlap with each other and (3) the prior knowledge net-
work also contains genes that are not present in the pathway compendium and that will act as
bridges between pathways. The extra connections allow ‘abnormal’ genes from outside the
pathway or from another datatype to contribute to the importance of a pathway for a particular
datatype. As a result, it is possible for a mutated gene to be similar to a sample without actually
being mutated in that particular sample. This can happen when the sample shares e.g. many
differentially expressed genes with several other samples that do exhibit mutations in that gene.
The calculation of a single aggregate pathway score is illustrated in Fig 2. First, the matrices
Sexp, Smut, Scnv and Smet are filtered so that they contain only genes that are present in the path-
way under study. For example, gene c is not present in pathway P (containing genes a,b and d).
Therefore, the third column of Sexp, corresponding to gene c, is removed. Next, for each filtered
submatrix separately, the average (over all samples and genes) of the remaining similarity val-
ues in Sexp, Smut, Scnv and Smet is calculated, resulting in a single score per input dataset
(ScorePexp; Score
P
cnv; Score
P
mut and Score
P
met).
Because a pathway’s score will be influenced by its size, and in order to eliminate random
effects, the scores-per-dataset are converted to p-values that reflect the probability of observing
(at least) the obtained score purely by chance. To achieve this, a large number of random gene
sets are created (in this study, we used 10,000 permutations, see implementation details below).
For each random set Ri, a score is calculated for each input dataset (ScoreRiexp; Score
Ri
cnv; Score
Ri
mut
and ScoreRimet) using the same approach as used for the pathway under study. The random score
distribution obtained for each dataset then allows for the calculation of the probabilities
pPexp; p
P
cnv; p
P
mut and p
P
met . Multiplying these p-values results in a single aggregate pathway score
that can be used to compare pathways.
The aggregate score should not be used as an absolute measure of relevance as it does not
correspond to a true joint-probability. The constituting probabilities calculated for each input
dataset will very likely be correlated. Consequently, the true joint probability of observing these
per-dataset similarity scores will likely be higher than the value obtained by multiplying the
individual p-values. However, we can assume that the correlation between the scores obtained
for each input dataset will be present for all pathways. Consequently, the aggregated score can
still be used to rank pathways. It has the additional advantage that it can be broken down into
four components that can be traced back to the input datasets.
Comparing the scores of pathways containing highly interconnected genes with scores
obtained for random sets of, most likely, unconnected genes may appear counter-intuitive:
the connectivity of the pathways might result in higher scores that could never be achieved by
sets of unconnected genes. However, the p-value of both a pathway and a random set of genes
is calculated using the average similarities obtained for individual genes. Those similarities in
turn are a function of the abnormal states observed in the different samples (the ‘ones’ in the
Pathway Relevance Ranking through Network-Based Data Integration
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input datasets), and of the way the gene is connected to other relevant genes in the network.
Importantly, a gene’s score is not determined by how well the gene connects to the other
genes that are present in the gene set under study, be it a pathway or a random gene set. Fur-
thermore, because all genes in the analysis are present in the prior knowledge network (genes
that are not present in the prior knowledge network were filtered out), all genes have neigh-
bors in the network. Consequently, it is perfectly possible for a gene of a random gene set to
be very important, either because it contains a lot of abnormal ‘ones’, or because it lies in a
network neighborhood containing other important genes that are not required to be present
in the random gene set.
As an alternative to the proposed permutation strategy, one could also permute the gene
labels of the input datasets, and each time measure the score for the pathway under study.
However, for each permutation, the computationally very expensive calculation of the similar-
ity matrix is required. As illustrated in S1 Fig, the probabilities obtained by the computationally
expensive permutation of the dataset gene labels are highly correlated (ρ>0.99) with the proba-
bilities obtained using the proposed method. Consequently the fast random gene set based per-
mutation strategy was used for all subsequent analysis.
Data binarization. In order to integrate an omics dataset in the global network represen-
tation, it needs to be converted into a list of qualitative gene-sample links or relations. Each
entry in each input dataset is converted into either ‘0’ or ‘1’, representing respectively the
absence or the presence of a meaningful link between a sample an a gene in the global network.
Although many binarization strategies are possible, the most trivial approach was adopted: a
hard threshold was set to the (absolute) values in a dataset. The dataset-dependent threshold is
chosen in such a way that the fraction of entries in each data matrix that is set to ‘1’ is as a close
as possible to a predefined parameter. In order to find the per-dataset threshold, a naive itera-
tive procedure is used. This procedure is applied to all but the mutation datasets. The latter are
already binary and are included without further filtering.
Data
Gene expression, mutation, methylation and copy number data. For breast cancer,
mRNA, mutation and copy number data were downloaded from The Cancer Genome Atlas
(TCGA, https://tcga-data.nci.nih.gov/tcga) in November 2012 (corresponding to the data from
[9]), and methylation data were downloaded in October 2013. 463 patients had data points for
all data types and were retained in the final analysis. The ovarian cancer datasets were down-
loaded from TCGA in April 2014, and contained mRNA, mutation, methylation and copy
number data for 447 patients. All breast and ovarian cancer data used in this study are part of
the TCGA open access data tier containing only de-identified and anonymized data. For breast
cancer, we focused on patients with Her2, Basal, Luminal A and Luminal B tumors. Patients
with Normal-like tumors were omitted from the analysis because of the low number of avail-
able samples. All gene identifiers were mapped to Entrez gene identifiers. Genes that could not
be mapped were left out of the analysis.
To reduce the problem size, all datasets were filtered to contain only genes that are present
in the prior knowledge interaction network (see below). For the mRNA datasets, this resulted in
a final selection of 10100 and 9463 genes for respectively breast cancer and ovarian cancer.
Expression data were centered on the median of the available normal samples, and made binary
according to the procedure laid out in the Method section. Rather than corresponding to abso-
lute high or absolute low expression values, the binary data will reflect whether a gene was dif-
ferentially expressed, relative to normal tissue data. No variance scaling was applied as this
would increase the impact of noise for genes with very low and constant normal expression.
Pathway Relevance Ranking through Network-Based Data Integration
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The mutation data were preprocessed using MutSig [13]. In order to obtain a broader selec-
tion (with a possibly high number of false positives), we used unadjusted p-values with a cut-
off of 0.05. For breast cancer, the final mutation dataset contained 465 mutated genes with
Entrez identifiers. For the ovarian cancer dataset, an identical procedure was employed result-
ing in 327 genes.
Copy number data for breast cancer and ovarian cancer were processed in the same way.
Significant copy number regions were identified with GISTIC2.0 [23] using the same parame-
ter settings as in the TCGA breast cancer overview [9]. The final dataset contained 446 and
2806 genes for respectively breast cancer, and ovarian cancer. The copy number data were
made binary by applying a threshold to the absolute value of the copy number variation,
according to the binarization strategy described above.
The methylation data were downloaded from TCGA and filtered using the procedure and
parameters described in the ovarian cancer study of the Cancer Genome Atlas Network [16].
Summarizing, hyper-and hypo-methylated genes are kept in the data set only if the following
conditions are fulfilled (parameters are for hyper-methylated genes and correspond to respec-
tively relaxed and strict settings in the filtering procedure, for hypo-methylated genes the pro-
cedure is adjusted in a trivial way). (1) In normal tissue, the gene should only slightly be
methylated (<0.5,<0.4). (2) The 90th percentile methylation level of tumor samples should be
considerably higher (0.1, 0.3) than the average normal methylation level. (3) The average gene
expression of normal samples should be considerably lower (2, 3 fold) than the average gene
expression of the 10% highest methylation levels in tumor samples. (4) There should exist a
negative spearman correlation (<-0.2,<-0.3) between the methylation level and the gene
expression level. Applying this procedure resulted in 624 hyper-methylated and 270 hypo-
methylated genes for breast cancer and 42 hyper-methylated and 173 hypo-methylated genes
for ovarian cancer. All methylation data are transformed from the [0,1] range to the [-0.5,0.5]
range by subtracting 0.5. The methylation data were made binary according to the same binari-
zation strategy used for the other data types.
Network data. KEGG pathway data [24] were downloaded on November 11, 2014 using
the KEGG REST-API functionality. 224 pathways (disease pathways were left out of the analy-
sis) were merged to constitute a single network. Non-gene entities (groups and complexes) in
the KEGG topology were expanded using dummy genes (with unique identifiers) that were
connected to the individual genes constituting the group or complex. Interacting genes with
such groups or complexes are then connected with the dummy genes rather than with the con-
stituting genes. Because the goal is to capture and use patterns of regulation, transcription fac-
tors and their targets were explicitly added. Transcription factor—target interactions were
obtained from http://encodenets.gersteinlab.org/ which is part of the ENCODE project [25].
Only interactions based on proximal TFBS data were included in the final network. The final
network contained 12040 genes and 97482 interactions.
Parameter tuning and implementation details
The presented procedure is controlled by two parameters: the Laplacian Exponential Diffusion
α parameter, and the desired fraction of entries in each dataset that will be set to ‘ 1‘ in the data
binarization process. The diffusion parameter α was set to 0.01 for all experiments (for both
breast cancer and ovarian cancer), but comparative experiments revealed that the obtained
pathway rankings are stable for values of α between 0.0001 and 0.05. The average number of
relations between genes and patient samples was set to 0.1 for all datasets.
The method was implemented in Matlab, and run on a 16-core, 64bit CentOS 6.2 system
with 128GB of memory. Source code and sample data is available from http://bioinformatics.
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intec.ugent.be/pathwayranking/. The calculation of the matrix exponential determines runtime
and memory usage which are known to be O(N3) and O(N2) respectively, with N the number of
entities in the global network. To reduce runtime and memory requirements, the global adja-
cency matrix was compressed by merging the mRNA expression dataset with the prior knowl-
edge network, resulting in a substantial reduction of problem size. The problem size N was
further reduced by filtering out all genes that were not present in the prior knowledge network.
The duration of the pathway ranking procedure is a linear function of the number of random
permutations which is in turn depending on the desired minimum obtainable p-value. If a
minimum p-value of 0.0001 is needed, scores for 10,000 permutations need to be calculated.
Calculating scores for permutations is a problem that is so-called embarrassingly parallel
(scores for individual permutations are independent of each other) indicating that the proce-
dure is easily sped up in a multi-core environment. On the system used, the processing of a typ-
ical analysis run (with 10,000 permutations) was finished in less than 40 minutes.
Results and Discussion
Pathway importance ranking for breast cancer subtypes
The importance of 224 non-disease KEGG pathways was assessed for each of the breast cancer
subtypes by calculating a relevance score per pathway for each breast cancer PAM50 subtype
(Basal-like, HER2, Luminal A, Luminal B) (Fig 3). Each relevance score is an aggregate of four
components: mRNA expression, copy number, mutation and methylation. The application to
breast cancer tumors serves as a validation of the newly developed method. The molecular
PAM50 breast cancer subtypes have been extensively characterized [9], and the ranking proce-
dure should recapitulate to a large extent what is known about these subtypes.
In general, the gene expression score component (or sub-score) is larger than the other com-
ponents. This is to be expected, because the sub-scores reflect the probability of observing a
particular expression, mutation, copy number or methylation pattern purely by chance. If a
pathway is truly relevant for a subtype, we expect (1) that this is reflected by differential expres-
sion of a set of genes in that pathway, and (2) that the expression pattern of genes in that path-
way will be consistent for tumor samples within that subtype (the downstream effect of a
genetic aberration on gene expression will be similar). Conversely, mutation, copy number and
methylation sub-scores are expected to be lower than the expression sub-score, since (1) onco-
genic aberrations are sparse and (2) pathway-disturbing alterations often are not consistent
even when they result in an identical downstream gene expression pattern (see the Introduc-
tion section). Furthermore, the subtypes are determined using a gene expression-based classi-
fier. This ensures similar gene expression values for at least the genes that are present in the
classifier. The more consistent genes behave within a single subtype, the higher the similarities
between the samples and the genes of a pathway will be and the less likely such similarities will
be observed purely by chance.
Subtype-independent pathways. The (mitotic) cell cycle pathway is the highest scoring
pathway for the Basal-like subtype, but it is also ranked high for the HER2 and the Luminal B
subtypes. It is absent in the top 20 for the Luminal A subtype. Closer inspection of the compo-
nents making up the aggregate score (Fig 3, S2 Fig) indicates that the score is highly determined
by a substantial copy number (predominantly transcription factor MYC, cyclin CCND1 and
the MDM2 oncogene) and mutation (tumor suppressor TP53) component. Mutations of TP53
are absent in Luminal A tumors, explaining the low score of this pathway for that subtype. The
HER2 and the Luminal B subtype also exhibit a small methylation component that appears to
be determined by the methylation status of the CCND1 and CCND2 cyclins, CDKN1C (a neg-
ative regulator of cell proliferation) and the chromatin binding MCM5 protein (S2 Fig).
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The PI3K-Akt signaling pathway, responsible for cell survival and proliferation through reg-
ulation of the AKT protein kinase, scores uniformly high for all subtypes. Yet, even though the
constituting score components are of a similar order of magnitude for all subtypes, the actual
genetic disturbances are diverse (S3 Fig). For instance, all subtypes exhibit mutations in this
pathway, but for the Basal-like tumors, this is limited to a single gene (TP53), whereas the
HER2 subtype is characterized by a combination of mutations in TP53 and the PIK3CA kinase.
The Luminal A and B subtypes are characterized by fewer mutations in TP53, complemented
with a combination of mutations in, among others, PIK3CA, the AKT1 kinase, the PTEN phos-
phatase and KRAS, a kinase and well-known proto-oncogene. A similar pattern can be
observed from the copy number data, where in Basal-like tumors, a uniform amplification pat-
tern is observed for MYC and PIK3CA, whereas the other subtypes exhibit a combination of
amplified MYC, CCND1, MDM2, IKBKB (a serine kinase), MCL1 (involved in apoptosis regu-
lation) and RPS6KB1 (a protein kinase). Finally, the presence of the Basal-like—HER2 –Lumi-
nal A—Luminal Bmethylation gradient (S3 Fig) is reflected in the presence of a small
methylation component that increases in size according to the same gradient.
Fig 3. The 20 highest ranking pathways for each of the four breast cancer subtypes. The aggregate score assigned to each pathway can be
decomposed into 4 probabilistic components. The contribution of each component to the total score is indicated in a different color bar: mRNA expression
(dark blue), copy number (light blue), mutation (green) and methylation (yellow).
doi:10.1371/journal.pone.0133503.g003
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Because the Jak-STAT signaling pathway, involved in cytokine and growth factor signaling,
shares many genes with the PI3K-Akt signaling pathway (e.g. MYC, CCND1, MYC, AKT1,
AKT2, PIK3CA, and the PIK3R1 kinase, see S4 Fig), it also scores uniformly high across all
subtypes. It scores lower than the PI3K-Akt signaling pathway because TP53 is not a member
of the pathway, nor many of the additional mutations (KRAS, PTEN) found in the PI3K-Akt
signaling pathway. This results in a smaller mutation component in the aggregate score (Fig 1).
The TGF-Beta signaling pathway scores very high for the Basal-like and Luminal A sub-
types, and intermediate (top 10) for the HER2 and Luminal B subtypes. It is involved in many
aspects of development biology, and in the regulation of a wide spectrum of cellular functions,
including proliferation and apoptosis [26]. Its role in breast tumor development is ambiguous
as TGF-Beta signaling can both suppress and promote cancer progression [27]. Interestingly,
its score is, for all subtypes, determined by a large methylation component. Indeed no other
pathway has (averaged over the subtypes) so large a methylation sub-score, which is remark-
able since only 6 genes of the pathway are present in the methylation dataset (S5 Fig). A possi-
ble explanation lies in the topology and size of this pathway. The TGF-Beta signaling pathway
representation in the KEGG database is relatively small and linear. This makes it easy to con-
nect upstream methylation events (almost all methylated genes in the pathway are found at the
start of the signaling cascade) with downstream expression effects, resulting in large similarity
scores for those genes. Together with the TGF-Beta signaling pathway, the presence of the
WNT signaling pathway for all subtypes but Luminal A is notable. For the Luminal B subtype,
theHippo signaling pathway is found too. These three pathways act as large cross-talking mod-
ules [26] and it has been suggested previously that these pathways play a prominent role in (tri-
ple negative) breast cancer development [15].
The pathways described above were all ranked high for (almost) all subtypes. Functionally,
these pathways take part in biological processes related to cell division, proliferation and sur-
vival. Their role in breast tumor development is well studied [9]. Interestingly, the underlying
disturbances leading to the high scores can be divers. Because disturbances are connected
through the a-priori network, the effect on the pathway score of a set of mutual exclusive muta-
tions or copy number alterations occurring in that pathway can equal (and indeed exceed) the
effect of a single consistent disturbance. This is clearly illustrated by the PI3K-Akt signaling
pathway, where similar scores are obtained for the Basal-like subtype exhibiting only TP53
mutations and MYC amplifications, and the other subtypes where TP53 mutations and MYC
amplifications are much sparser, but are complemented with other disturbances.
Subtype-specific pathways. Because the analysis was performed separately for each sub-
type, the method is expected to identify not only pathways that are active or important for all
subtypes, but also subtype-specific pathways. For a selection of differentially scoring pathways,
Fig 4 displays a comparison of scores obtained for the different subtypes.
The scores for the p53 signaling pathway are highly determined by the mutation status of
TP53 (S6 Fig) and consequently, the high score for the Basal-like subtype and the low score for
the Luminal A subtype are to be expected. P53 signaling is intricately related with a cell’s
response to, among others, DNA damage and activated oncogenes. Differential activation of
this pathway in combination with hormone receptor status is an important factor determining
breast cancer progression and outcome [28]. Even though Luminal B tumors too are only infre-
quently mutated in TP53, their score is much higher than for Luminal A tumors. A detailed
investigation of the expression data revealed that Luminal B tumors express much more genes
from the p53 signaling pathway than the Luminal A tumors do (S6 Fig), suggesting that the
aberrant activity of this pathway is not necessarily caused by defects in the pathway itself.
The Toll-like receptor signaling pathway, suspected to be involved in the tumor’s evasion of
the immune system [29], scores very high for the Basal-like subtype, intermediate for the
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Luminal A subtype, and low for the HER2 and Luminal B subtypes. The differences in scores
for the subtypes appear to be caused by differences in the amplification and mutation status of
PIK3CA, where again the lack of PIK3CA mutations in the Basal-like subtype are compensated
by additional copy number amplification of PIK3CA, copy number amplifications of the
MAP3K7 and RIPK1 kinases, copy number deletions in PIK3R1, and (slight) hypo-methyla-
tion of chemokine CCL5 and toll-like receptor TLR9 (S7 Fig).
The ErbB signaling pathway couples extra-cellular growth signals to intra-cellular signaling
pathways that eventually control cell survival, proliferation and motility. It is involved in
tumor development and progression, and many ErbB inhibitors are currently used therapeuti-
cally [30]. Its score is highly determined by the amplification state of the ERBB2 receptor tyro-
sine kinase and the mutation state of PIK3CA (S8 Fig). HER2 tumors exhibit an almost total
amplification of ERBB2 that translates immediately to the overexpression of ERBB2 in this sub-
type. Luminal A tumors lack the amplification of ERBB2 but are, like HER2 tumors, frequently
mutated in PIK3CA. Luminal B tumors are infrequently mutated in PIK3CA and exhibit infre-
quent ERBB2 amplification, whereas in Basal-like tumors PIK3CA is not mutated, nor is
ERBB2 amplified.
TheMAPK-signaling pathway is one of the few pathways (together with the AMPK path-
way, see below) that scores highest for the Luminal B subtype. The ample evidence that aber-
rant MAPK signaling promotes tumor cell proliferation, survival and metastasis, makes this
pathway an interesting inhibitory drug target [31]. MAP3K1, which is known for its critical
function in cell fate decisions, is one of the central genes of the pathway and is crucial in con-
necting upstream and downstream genes [32]. Consequently, the observed differences in scores
between the subtypes are expected to depend on its mutation status. Interestingly, although
MAP3K1 is more frequently mutated in Luminal A tumors (S9 Fig), the pathway score is
higher for the Luminal B tumors, and the mutation sub-score for Luminal B tumors is higher
Fig 4. Pathway scores compared across breast cancer subtypes for a selection of pathways.Dark
blue = Basal-like, light blue = HER2, green = Luminal A and yellow = Luminal B.
doi:10.1371/journal.pone.0133503.g004
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than for Luminal A tumors (Fig 3). This can be due to the fact that, like for the p53 signaling
pathway, the Luminal B tumors express more genes from this pathway and several genes are
(slightly) more methylated (S9 Fig). The more genes that are differentially expressed or methyl-
ated, the more connections exist (through the global network) between tumor samples and
mutated genes and the higher the similarity scores between the tumor samples and the mutated
genes will be. Conversely, the omnipresent mutations of TP53 in the Basal-like and HER2 sub-
types do not result in a particular higher score for these subtypes, since the topology of the
pathway is such that the connection between TP53 and the differentially expressed and methyl-
ated genes is less straightforward [24].
Like theMAPK signaling pathway, the AMPK signaling pathway, a sensor of cellular energy
status [24], scores very high for the Luminal B tumors, intermediate for Luminal A and HER2
tumors, and low for the Basal-like subtype. Here the pathway score can be explained (S10 Fig)
by the inter-subtype differences in PIK3CA mutations (absent in Basal-like tumors, very fre-
quent in Luminal A), copy number amplification of CCND1 and RPS6KB1 (unimportant in
Basal-like and Luminal A, frequent in HER2 and Luminal B) and copy number loss of PIK3R1
(Basal-like).
The analysis above indicates that the presented method is able to prioritize subtype-specific
pathway importance with the high score for the ErbB signaling pathway for the HER2 subtype
as a typical example. The results for the p53 andMAPK-signaling pathway confirm that the
integrated approach, where the analysis does not depend on a single gene nor a single type of
data, is relevant and results in pathway scores that do not merely reflect mutation or copy num-
ber alteration frequencies.
Comparison with alternative approaches. To put the proposed method into perspective,
we compared it to a naïve frequency-based approach. Instead of using, for each dataset, per-
gene aggregated network-based similarity scores, we used the frequency of occurrence of
‘abnormal’ states (i.e. the number of times a gene was differentially expressed, mutated, . . .
aggregated over all samples) as the individual gene score. Using the same permutation-based
approach as used for the proposed method, a p-value for each pathway can be obtained for
each dataset, and the p-values can be combined to result in a single frequency-based score per
pathway. This naïve approach was applied to the Luminal A breast cancer subtype, corre-
sponding to the largest group of patients in this study. The frequency-based pathway ranking
was performed on the same (filtered) datasets that were used to obtain the network-based
results. The results are displayed in S2 Table. In general, the two approaches agree: even though
224 pathways were evaluated, the 50 highest scoring pathways obtained with the proposed
method can almost all be found among the 50 highest scoring pathways obtained with the fre-
quency-based approach. However, the ordering of the pathways differs considerably between
the two methods. Several relevant high-scoring pathways (see Result section above) obtained
with the network-based method tend to be ranked lower by the frequency-based method, as is
exemplified by the MAPK signaling pathway. This clinically important pathway is ranked 14th
by the network– based method, but ranked only 32th by the frequency based approach. The
pathway exhibits, more than any other pathway, a dispersed pattern of mutual exclusive muta-
tions. The low mutation frequencies for individual genes result in a low rank when using only
frequency as a relevance criterion.
Next, we compared our pathway relevance assessment results with those mentioned in the
original PARADIGM publication [6]. Re-running PARADIGM with the same data used in our
experimental setup, including mutation and methylation data, was not possible. We found that
the top 15 pathways mentioned in the older PARADIGM study correspond to, or overlap
highly with at least one pathway of our top-ranked pathways for each subtype (S1 Table). The
only exception to this is the ‘p75(NTR)-mediated signaling pathway’ ranked 6 out of 15 in the
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original PARADIGM study. This pathway maps to the neurotrophin signaling pathway in this
study. In addition to the overlapping pathways, our approach also high-scored several other
pathways (e.g. TGF-Beta,WNT and Toll-like receptor signaling). This is to be expected since
firstly, in this study, additional datasets are used as input, and secondly, breast cancer subtypes
are analyzed separately rather than collectively.
Pathway importance ranking for ovarian cancer
For the ovarian cancer analysis, no molecular subtypes were used. Instead the 447 tumors were
stratified based on survival data. We assume that strong differences in survival have a molecu-
lar foundation, although this may not always be the case. Three groups were identified: a group
where patients were not alive 1000 days after the diagnosis (104 patients), a group that survived
for at least 2000 days (47 patients), and an intermediate group (296 patients). We investigated
whether the newly developed method is able to identify pathways that can help in explaining
the different outcome between these groups of patients. Similar to the breast cancer analysis,
the importance of 224 non-disease KEGG pathways was assessed for each of the survival-based
subtypes. In what follows, we focus on the similarities and differences between the most
extreme survival-based subtypes.
Important pathways common to all subtypes. Fig 5 displays the 20 highest scoring path-
ways for the two most extreme subtypes. From the figure, it is obvious that in general the patient
group with the worst outcome has higher pathway scores than the group with the best outcome.
Only theMAPK signaling and the cell cycle pathway exhibit similar aggregate scores. The fact
that many different pathways are scored differentially between the subtypes suggests that the
molecular explanation for the difference in survival will most likely not have a single cause.
In previous studies, as summarized in [16], a number of important deregulated pathways
have been related to ovarian cancer: RB-signaling (cell cycle), RAS/PI3K signaling (PI3K-Akt
signaling), FOXM1 (not present in the KEGG database, but overlapping with the cell cycle
pathway) and Notch signaling. In this study, the highest scoring pathways are theMAPK sig-
naling pathway, the cell cycle pathway, the PI3K-Akt signaling pathway and theWNT signaling
pathway. The absence of the Notch signaling pathway in the top 20 of highest scoring pathways
for either subtype is striking. A closer inspection of the actual data (S11 Fig) reveals that the
Notch signaling pathway harbors few (epi-) genetic disturbances, both in terms of disturbances
per gene as well as in terms of the number of disturbed genes. Additionally, as the KEGG repre-
sentation of the Notch signaling pathway only contains 24 genes, it is possible that the pathway
information is incomplete. However, a close cooperation betweenMAPK signaling and Notch
signaling has been described in other tumors [33], andMAPK signaling is top-scored for all
subtypes. The presence of theWNT signaling pathway, implicated previously in ovarian cancer
tumorigenesis [34,35], is noteworthy. Its high score will likely be determined (S12 Fig) by TP53
mutations and copy number amplification in e.g. MYC, the NDK2 kinase andWNT5B (encod-
ing for a signaling protein).
Differential subtype analysis. More than in the pathways that score uniformly high across
subtypes, we are interested in pathways that score differently for the survival-based patient
groups. To achieve that, we focused on the 20 highest scoring pathways for the bad-outcome
group. For each of these pathways, we calculated the ratio of the score for the bad-outcome
group and the corresponding score in the good-outcome group (Fig 6). The assumption is that
the larger a score ratio deviates from one, the more likely a pathway is involved in a process
that determines outcome.
The scores of the pathways in the bad-outcome group are consistently higher than the corre-
sponding scores in the good-outcome group, with the exceptions of the MAPK signaling and cell
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Fig 5. The 20 highest ranking pathways for the twomost extreme ovarian cancer survival-based subtypes. The contribution of each component to the
total score is indicated in a different color bar: mRNA expression (dark blue), copy number (light blue), mutation (green) and methylation (yellow).
doi:10.1371/journal.pone.0133503.g005
Fig 6. Ratio of bad-outcome pathway scores and the corresponding good-outcome scores. A ratio of ‘1’ indicates that the pathway scores equally high
for patients in the bad-outcome group and patients in the good-outcome group. Values larger than 1 indicate higher pathway importance / activity for the bad-
outcome group. Pathways shown are limited to the top-20 highest scoring pathways in the bad-outcome group.
doi:10.1371/journal.pone.0133503.g006
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cycle pathways yielding score ratios respectively equal to 0.97 and 0.94. The highest score ratios
are found for Jak-STAT signaling, ECM receptor interaction, cAMP signaling, TGF-Beta signaling
and estrogen signaling. S14–S18 Figs illustrate that single (epi-)genetic aberrations cannot be eas-
ily linked to the differential scoring of these 5 pathways, except for slight increases in MYC,
CACNA1D (a Calcium channel) and KRAS amplification, and infrequent CREBBP (a transcrip-
tion factor activator) mutations. Still, all five pathways are involved in tumor development and
proliferation. Jak-STAT signaling is since long linked to cell migration and survival in ovarian
cancer [36] and often, the expression of, or the responsiveness to TGF-Beta is lost, leading to cell
proliferation [37]. Furthermore, it is known that the disruption of the extra cellular matrix (ECM
interaction) can lead to the overproduction of growth factors that promote abnormal prolifera-
tion [38]. Estrogen signaling is thought to be involved in the establishment of a pro-tumorigenic
micro-environment, and the long-term use of estrogen-only hormone replacements is linked to
ovarian cancer development [39]. Finally, cAMP signaling is involved in cell survival in ovarian
cancer and the presence of mutant CREBBP proteins can lead to tumorigenesis [40].
Interestingly, when all pathways are considered instead of only the pathways that are impor-
tant for the bad-outcome patient group, the ratio score ranking (S13 Fig) is topped by the Notch
signaling pathway event though this pathway is not high-scored for any patient group. As men-
tioned above, Notch signaling is involved in embryonic development, proliferation, differentia-
tion and apoptosis, and is implicated in ovarian (and many other) cancers [16,41,42]. Its large
score ratio could be attributed to the differential amplification of DLL3 (S11 Fig), which
recently has been reported to be the second most altered gene in the NOTCH3 pathway [43].
Conclusions
We have presented a new pathway importance ranking strategy that allows for the integration
of any dataset that can be cast in a binary format. The method was evaluated on two datasets
retrieved from TCGA, containing gene expression, mutation, copy number and methylation
data for breast and ovarian tumors.
By applying the method to the well-studied breast cancer TCGA dataset, we demonstrated
the method’s potential to identify key pathways, involved in breast cancer development, that are
important for all molecular subtypes. The method recapitulates to a large extent what is known
about breast cancer pathway activity. Interestingly, sometimes pathways were deemed equally
important for different subtypes, yet the underlying (epi)-genetic disturbances were diverse. Fur-
thermore, next to prioritizing universally high-scoring pathways, the pathway ranking method
was able to identify subtype-specific pathways. Often the aggregate score of a pathway could not
be motivated by a single mutation, copy number or methylation alteration, but rather by a com-
bination of genetic and epi-genetic disturbances. This suggests that the integration of all data
through a network of known gene interactions is an essential step in tumor analysis.
The analysis of ovarian tumors confirmed the method’s ability to correctly identify key path-
ways, irrespective of survival-based tumor subtypes. A differential analysis of survival-based
subtypes revealed several pathways with higher importance for the bad-outcome patient group
than for the good-outcome patient group. Many of the pathways exhibiting higher importance
for the bad-outcome patient group could be related to tumor proliferation and survival.
Supporting Information
S1 Fig. Comparison of scores obtained by two permutation strategies. Scores for shuffled
pathways (10000 permutations, X-axis) are plotted against the scores obtained after shuffling
the gene labels of the input datasets (100 permutations, Y-axis). The correlation is> 0.99.
(TIF)
Pathway Relevance Ranking through Network-Based Data Integration
PLOS ONE | DOI:10.1371/journal.pone.0133503 July 28, 2015 17 / 22
S2 Fig. Cell cycle pathway summary for breast cancer.mRNA gene expression, mutation pat-
tern, copy number status and methylation pattern for the genes of the cell cycle KEGG pathway
(hsa4110). Red = high value/presence, blue = low value. Methylation data are rescaled to the
interval [0,1]. Genes are sorted according to the significance of a Kruskal-Wallis test, with the
subtype as categorical factor. Maximum 30 genes per data type are shown.
(TIF)
S3 Fig. PI3K-Akt signaling pathway summary for breast cancer.mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the PI3K-Akt
signaling KEGG pathway (hsa4151). Red = high value/presence, blue = low value. Methylation
data are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Krus-
kal-Wallis test, with the subtype as categorical factor. Maximum 30 genes per data type are
shown.
(TIF)
S4 Fig. Jak-STAT signaling pathway summary for breast cancer.mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the Jak-STAT
signaling KEGG pathway (hsa4630). Red = high value/presence, blue = low value. Methylation
data are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Krus-
kal-Wallis test, with the subtype as categorical factor. Maximum 30 genes per data type are
shown.
(TIF)
S5 Fig. TGF-Beta signaling pathway summary for breast cancer.mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the TGF-Beta
signaling KEGG pathway (hsa4350). Red = high value/presence, blue = low value. Methylation
data are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Krus-
kal-Wallis test, with the subtype as categorical factor. Maximum 30 genes per data type are
shown.
(TIF)
S6 Fig. p53 signaling pathway summary for breast cancer.mRNA gene expression, mutation
pattern, copy number status and methylation pattern for the genes of the p53 signaling KEGG
pathway (hsa4115). Red = high value/presence, blue = low value. Methylation data are rescaled
to the interval [0,1]. Genes are sorted according to the significance of a Kruskal-Wallis test,
with the subtype as categorical factor. Maximum 30 genes per data type are shown.
(TIF)
S7 Fig. Toll-like receptor signaling pathway summary for breast cancer.mRNA gene expres-
sion, mutation pattern, copy number status and methylation pattern for the genes of the Toll-
like receptor signaling KEGG pathway (hsa4620). Red = high value/presence, blue = low value.
Methylation data are rescaled to the interval [0,1]. Genes are sorted according to the signifi-
cance of a Kruskal-Wallis test, with the subtype as categorical factor. Maximum 30 genes per
data type are shown.
(TIF)
S8 Fig. ErbB signaling pathway summary for breast cancer.mRNA gene expression, muta-
tion pattern, copy number status and methylation pattern for the genes of the ErbB signaling
KEGG pathway (hsa4012). Red = high value/presence, blue = low value. Methylation data are
rescaled to the interval [0,1]. Genes are sorted according to the significance of a Kruskal-Wallis
test, with the subtype as categorical factor. Maximum 30 genes per data type are shown.
(TIF)
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S9 Fig. MAPK signaling pathway summary for breast cancer.mRNA gene expression, muta-
tion pattern, copy number status and methylation pattern for the genes of the MAPK signaling
KEGG pathway (hsa4010). Red = high value/presence, blue = low value. Methylation data are
rescaled to the interval [0,1]. Genes are sorted according to the significance of a Kruskal-Wallis
test, with the subtype as categorical factor. Maximum 30 genes per data type are shown.
(TIF)
S10 Fig. AMPK signaling pathway summary for breast cancer.mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the AMPK sig-
naling KEGG pathway (hsa4152). Red = high value/presence, blue = low value. Methylation
data are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Krus-
kal-Wallis test, with the subtype as categorical factor. Maximum 30 genes per data type are
shown.
(TIF)
S11 Fig. Notch signaling pathway summary for ovarian cancer.mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the Notch sig-
naling KEGG pathway (hsa4330). Red = high value/presence, blue = low value. Methylation
data are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Krus-
kal-Wallis test, with the subtype as categorical factor ( = p<0.05,  = p<0.01,  = p<0.001).
No FDR correction was applied. Maximum 30 genes per data type are shown.
(TIF)
S12 Fig. WNT signaling pathway summary for ovarian cancer.mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the WNT sig-
naling KEGG pathway (hsa4310). Red = high value/presence, blue = low value. Methylation
data are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Krus-
kal-Wallis test, with the subtype as categorical factor ( = p<0.05,  = p<0.01,  = p<0.001).
No FDR correction was applied. Maximum 30 genes per data type are shown.
(TIF)
S13 Fig. Ratio of bad-outcome pathway scores and the corresponding good-outcome scores
for 100 pathways. A ratio of ‘1’ indicates that the pathway scores equally high for patients in
the bad-outcome group and patients in the good-outcome group. Values larger than 1 indicate
higher pathway importance / activity for the bad-outcome group.
(TIF)
S14 Fig. Jak-STAT signaling pathway summary for ovarian cancer.mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the Jak-STAT
signaling KEGG pathway (hsa4630). Red = high value/presence, blue = low value. Methylation
data are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Krus-
kal-Wallis test, with the subtype as categorical factor ( = p<0.05,  = p<0.01,  = p<0.001).
No FDR correction was applied. Maximum 30 genes per data type are shown.
(TIF)
S15 Fig. ECM-receptor interaction pathway summary for ovarian cancer.mRNA gene
expression, mutation pattern, copy number status and methylation pattern for the genes of the
ECM-receptor interaction KEGG pathway (hsa4512). Red = high value/presence, blue = low
value. Methylation data are rescaled to the interval [0,1]. Genes are sorted according to the sig-
nificance of a Kruskal-Wallis test, with the subtype as categorical factor ( = p<0.05,  =
p<0.01,  = p<0.001). No FDR correction was applied. Maximum 30 genes per data type are
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shown.
(TIF)
S16 Fig. cAMP signaling pathway summary for ovarian cancer.mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the cAMP sig-
naling KEGG pathway (hsa4024). Red = high value/presence, blue = low value. Methylation
data are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Krus-
kal-Wallis test, with the subtype as categorical factor ( = p<0.05,  = p<0.01,  = p<0.001).
No FDR correction was applied. Maximum 30 genes per data type are shown.
(TIF)
S17 Fig. TGF-Beta signaling pathway summary for ovarian cancer.mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the TGF-Beta
signaling KEGG pathway (hsa4350). Red = high value/presence, blue = low value. Methylation
data are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Krus-
kal-Wallis test, with the subtype as categorical factor ( = p<0.05,  = p<0.01,  = p<0.001).
No FDR correction was applied. Maximum 30 genes per data type are shown.
(TIF)
S18 Fig. Estrogen signaling pathway summary for ovarian cancer.mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the Estrogen
signaling KEGG pathway (hsa4915). Red = high value/presence, blue = low value. Methylation
data are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Krus-
kal-Wallis test, with the subtype as categorical factor ( = p<0.05,  = p<0.01,  = p<0.001).
No FDR correction was applied. Maximum 30 genes per data type are shown.
(TIF)
S1 Table. Mapping of the top-scoring pathways from the original PARADIGM study on
KEGG pathways.
(XLSX)
S2 Table. Comparison of the proposed, network-based method (SIM) to a naïve frequency-
based approach (FRQ). Pathway IDs correspond to KEGG identifiers.
(PDF)
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